Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

10,000 seniors studied to predict fatty liver dangers

NCT ID NCT07537829

Knowledge-focused Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 10,000 older adults (age 60+) with fatty liver disease to find out what increases their risk for serious liver problems like scarring, cirrhosis, or liver cancer. Researchers used medical records and yearly check-ups to build a computer model that predicts these risks. The study did not test any treatments—it only observed and analyzed existing data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

10,000 people

The number who actually took part.

Started

Jan 2018

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is derived from the Nanjing Elderly Steatotic Liver Disease Cohort, which includes individuals aged ≥60 years with imaging or biopsy-confirmed hepatic steatosis. Participants underwent annual health examinations from 2018 to March 2026. Data on demographics, lifestyle, anthropometrics, laboratory tests, abdominal ultrasound, and medication use were collected. All data were retrospectively extracted from medical records and the cohort database.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥60 years * Presence of hepatic steatosis confirmed by baseline imaging (e.g., ultrasound, transient elastography) or liver biopsy Exclusion Criteria: * Missing data for key variables * Pre-existing hepatocellular carcinoma or history of liver transplantation at baseline

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction-associated steatotic liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcoholic fatty liver disease cirrhosis of liver fatty liver disease metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction-associated steatotic liver disease Steatotic liver disease

Contacts and locations

Locations

  • Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

    Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.